But many panel members said J. & J. recipients might also benefit from the option of a Pfizer-BioNTech or Moderna booster, an action that an F.D.A. official said was possible.
read more
Source: NY Times
03:06, October 16, 2021
Sharon LaFraniere, Noah Weiland and Carl Zimmer